Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Intervention:   Drug: FCN-159 Sponsor:   Shanghai Fosun Pharmaceutical Development Co, Ltd. Not yet recruiting

Source: ClinicalTrials.gov - July 8, 2021 Category: Research Source Type: clinical trials